Sequence: Stearyl-AGYLLGKLLOOLAAAALOOLL-NH2
| Experiment Id | EXP001412 |
|---|---|
| Paper | Calcium condensed cell penetrating peptide complexes offer highly efficient, low toxicity gene silen |
| Peptide | TAT |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | Varied via N/P ratio (7–33 screened); optimized ~N/P 25 |
| Rna Concentration | 10, 25, or 50 nM (5 h incubation; readout at 48 h) |
| Mixing Ratio | N/P ratio 7, 13, 18, 25, 33 (varied); CaCl2 23.1–69.2 mM added post-complexation |
| Formulation Format | Calcium-condensed CPP/siRNA nanoparticles |
| Formulation Components | TAT + siRNA + CaCl2 (final 23.1–69.2 mM) |
| Size Nm | 60.00 |
| Zeta Mv | 15.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | A549-luc-C8 (human lung epithelial reporter cell line) |
| Animal Model | |
| Administration Route | |
| Output Type | Luciferase knockdown (% of control; normalized to total protein) |
| Output Value | |
| Output Units | |
| Output Notes | High silencing only when CaCl2 added; best formulations at high CaCl2 (69.2 mM) and moderately high N/P (≈25) achieved ~92% knockdown (≈8.3% luciferase remaining) at 50 nM. |
| Toxicity Notes | No cytotoxicity observed for TAT complexes in A549-luc-C8; free TAT showed negligible cytotoxicity up to 5 mg/mL (MTS assay). |
| Curation Notes |